相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
J. Alfred Witjes et al.
EUROPEAN UROLOGY (2017)
Overexpression of ribonucleotide reductase subunit M1 protein predicts shorter survival in metastatic bladder cancer patients treated with gemcitabine-containing combination chemotherapy
Nagahide Matsumura et al.
INTERNATIONAL JOURNAL OF UROLOGY (2017)
Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma
Morihiko Sagawa et al.
CLINICAL CANCER RESEARCH (2017)
Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine
Cody S. Lee et al.
GENES & DISEASES (2017)
Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells
Yoshimasa Tokunaga et al.
EUROPEAN JOURNAL OF CANCER (2015)
G Protein-Coupled Receptor 87 (GPR87) Promotes Cell Proliferation in Human Bladder Cancer Cells
Xia Zhang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy
Miso Kim et al.
PLOS ONE (2015)
Adenovirus: The First Effective In Vivo Gene Delivery Vector
Ronald G. Crystal
HUMAN GENE THERAPY (2014)
Expression of ribonucleoside reductase subunit M1, but not excision repair cross-complementation group 1, is predictive in muscle-invasive bladder cancer treated with chemotherapy and radiation
Mark Shilkrut et al.
MOLECULAR AND CLINICAL ONCOLOGY (2014)
First- and second-line therapy for metastatic urothelial carcinoma of the bladder
F. A. Yafi et al.
Current Oncology (2011)
The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer
Lars Petter Jordheim et al.
LANCET ONCOLOGY (2011)
Chemosensitization of gemcitabine-resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the anti-apoptotic gene, clusterin
Mototsugu Muramaki et al.
BJU INTERNATIONAL (2009)
Clinical pharmacology and pharmacogenetics of gemcitabine
Andrea Wong et al.
DRUG METABOLISM REVIEWS (2009)
Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells
Y. Nakano et al.
BRITISH JOURNAL OF CANCER (2007)
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer - A Randomized controlled trial
Helmut Oettle et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Systemic chemotherapy in locally advanced and/or metastatic bladder cancer
D. Pectasides et al.
CANCER TREATMENT REVIEWS (2006)
Intravesical gemcitabine: A phase 1 and pharmacokinetic study
JA Witjes et al.
EUROPEAN UROLOGY (2004)
An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines
JD Davidson et al.
CANCER RESEARCH (2004)
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
JH Schiller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients
JP Stein et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Single-agent gemcitabine is active in previously treated metastatic breast cancer
M Spielmann et al.
ONCOLOGY (2001)
Gemcitabine and cisplatin versus methotrexate vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large randomized, multinational, multicenter, phase III study
H von der Maase et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
